Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10898444 | SPIL | Extended release multiparticulates of ranolazine |
Jan, 2038
(14 years from now) | |
US11510878 | SPIL | NA |
Jan, 2038
(14 years from now) |
Market Authorisation Date: 28 February, 2022
Treatment: NA
Dosage: GRANULES, EXTENDED RELEASE;ORAL
2
United States
1
India
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic